Patients who have heterozygous familial hypercholesterolemia (HeFH), a condition that causes abnormally raised low-density lipoprotein cholesterol (LDL-C) levels and premature cardiovascular disease, ...
"This is about starting the data story at the source," said Charles Hutka, Chief Commercial Officer at StafaCT. "When apheresis data is captured directly -- across both collection and therapeutic ...
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Results From the CANOPY-1 Trial The study included CAR T-cell ...
Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...
Approximately 30%-40% of patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) infused with CD19-targeted chimeric antigen receptor (CAR) T cells achieve durable responses. Consensus ...
An acute reduction in total cholesterol of ≥65%, or in LDL cholesterol of ≥70%, during each procedure; An interval mean total cholesterol of <7 mmol/l or LDL cholesterol <6.5 mmol/l (or decreases of ...
During a live event, Binod Dhakal, MD, discussed the rationale for choosing therapy given before CAR T-cell infusion in multiple myeloma.
There is limited information on the pharmacotherapeutic management of children with homozygous FH from birth onwards, especially with regards to the initiation of drug treatment. However, clinicians ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results